Skip to content

Application of new ultrasound technology in hormone-related diseases

Application of new ultrasound technology in hormone-related diseases

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044140
Enrollment
Unknown
Registered
2021-03-11
Start date
2021-03-15
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone-related diseases

Interventions

Gold Standard:Pathological diagnosis or clinical diagnosis
ultrasound&#32
technology&#32

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Retrospective study: Patients with thyroid nodules who underwent thyroid surgery or FNA at the China-Japan Friendship Hospital from 2003 to 2021; patients with thyroid nodules who underwent ultrasound examinations at the China-Japan Friendship Hospital before surgery and followed up with regular ultrasound. Prospective study: patients diagnosed with PTMC by ultrasound and FNA in this hospital; those who agree to undergo elastography, contrast-enhanced ultrasound, FNA-Tg and genetic examination; FNA/thyroid glands undergoing ultrasound diagnosis and follow-up in this hospital before and after surgery Patients with nodules. Or (2) Women attending the obstetrics and gynecology outpatient or inpatient department of China-Japan Friendship Hospital, and group them according to their menstrual history. Or (3) Adult patients who are planned to undergo bariatric surgery in the weight loss center of our hospital with relevant indications for surgery.

Exclusion criteria

Exclusion criteria: (1) Patients with other malignant tumors; patients with other immune system diseases; patients with severe heart and lung diseases; patients with other important organ tumors; patients with incomplete imaging data or case data; (2) History of adverse pregnancy: such as twins, giant babies, acute birth, premature birth, etc.; patients with pelvic surgery; those with a history of estrogen therapy; those with serious complications that cannot cooperate with gynecological ultrasound; (3) Liver disease of other causes: alcoholic liver disease, the amount of alcohol consumed by the patient is more than 140 g per week for men and more than 70 g per week for women. Viral hepatitis, drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration, autoimmune liver disease and other specific diseases can lead to fatty liver.

Design outcomes

Primary

MeasureTime frame
new ultrasound technology;Elastography;Contrast-enhanced ultrasound;Ththree-dimensional ultrasound;

Countries

China

Contacts

Public ContactBo Zhang

Department of Ultrasound, China-Japan Friendship Hospital

779053916@qq.com+86 10-84205417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026